Enlivex's GVHD drug Apocell receives orphan status from FDA

04/5/2013 | Globes (Israel)

The FDA has granted orphan-drug designation to Enlivex Therapeutics' Apocell, an experimental drug for graft-versus-host disease. The designation will give the drug seven years of market exclusivity and "significant regulatory easements, which we believe will shorten marketing approval of the drug in the U.S., reducing costs," Enlivex CEO Alon Moran said.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
PRINCIPAL ENGINEER - R&D - 14000009CP
Abbott
Chicago, IL